Skip to content

The Serum Tissue Factor Level in Lung Cancer Patients as a Prognostic Factor

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00257179
Enrollment
200
Registered
2005-11-22
Start date
2005-06-30
Completion date
Unknown
Last updated
2006-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Tissue factor, Lung cancer, Tissue factor protein inhibitor, Factor VII, Factor X

Brief summary

This study uses serum tissue factor and tissue factor inhibitor and factor VII to monitor the pre-coagulation status in lung cancer patients and to correlate the pre-coagulation status with clinical staging and prognosis.

Detailed description

The staging of lung cancer was according to tumor size, involvement of lymph node and metastatic status. But there is a different prognosis in cancer patients of the same stage. The coagulation status of cancer patients was considered as an important possible prognostic factor. So in this study, we want to evaluate patients' coagulation status and find the relation of coagulation status and cancer status. We thus propose a prospective study using coagulation factors in order to search for the relationship between cancer stage and pre-coagulation status in Taiwanese lung cancer patients. We will also evaluate the potential use of tissue factor as a prognosis predictor in lung cancer patients.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
NATURAL_HISTORY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with newly-diagnosed lung cancer * Serum from cancer-free healthy volunteers

Exclusion criteria

* Chronic renal failure or end-stage renal disease \[ESRD\] (creatinine \[Cr\] \> 2 ) * Hyperlipidemia on statin therapy * Acute myocardial infarction * Tapal or Plavix use * Active thromboembolic event * Severe liver disease (\> child B)

Countries

Taiwan

Contacts

Primary ContactChong-Jen Yu, M.D., Ph.D.
jeffery@ha.mc.ntuh.edu.tw886-2-2356-2905

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026